Andrew Hill is a senior visiting Research Fellow, Pharmacology Department, Liverpool University. His main research focus is antiretroviral treatment for resource-limited settings. He advises the Clinton and the Bill and Melinda Gates Foundations, designing clinical trial programmes of antiretroviral dose optimisation. After graduating from Oxford University, he completed a PhD at Amsterdam University. Since 1992, he has worked on the antiretroviral drug development, starting with 3TC at GlaxoWellcome and later saquinavir at Roche. He consults for Tibotec on clinical trial programmes for darunavir, etravirine, and rilpivirine. Involved in the use of HIV RNA and CD4 counts in the regulatory approval of antiretrovirals, the standardisation of HIV clinical trial analyses, and several systematic reviews of HIV clinical trials, his work on lower doses of d4T led the World Health Organisation to reduce the recommended dose from 40mg to 30mg BID. Dr. Hill has authored over 40 research papers on HIV. He was on the editorial board of AIDS and is currently an editor for the Journal of Antimicrobial Chemotherapy. He runs a charity “Living and Loving” that supports children living with HIV in Thailand. This year, he is running the London Marathon to support a children’s HIV project in South Africa.